Journey Medical Corporation (DERM) Revenue History
Annual and quarterly revenue from 2014 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
DERM Revenue Growth
Revenue Breakdown (FY 2024)
DERM's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
DERM Revenue Analysis (2014–2024)
As of May 8, 2026, Journey Medical Corporation (DERM) generated trailing twelve-month (TTM) revenue of $56.4 million, reflecting modest growth of +1.0% year-over-year. The most recent quarter (Q2 2025) recorded $15.0 million in revenue, up 14.2% sequentially.
Looking at the longer-term picture, DERM's 5-year compound annual growth rate (CAGR) stands at +10.0%, indicating steady revenue expansion. The company achieved its highest annual revenue of $79.2 million in 2023.
Revenue diversification analysis shows DERM's business is primarily driven by Qbrexza (49%), Accutane (38%), and Amzeeq (10%).
When compared to Healthcare sector peers including SKIN (-8.2% YoY), PRGO (-3.6% YoY), and NVCR (+8.5% YoY), DERM has underperformed the peer group in terms of revenue growth. Compare DERM vs SKIN →
DERM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DERMCurrent | $56M | +1.0% | +10.0% | -24.4% | |
 SKIN | $301M | -8.2% | +20.4% | -6.9% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 PODD | $2.7B | +31.9% | +24.5% | 17.5% | |
 VYNE | $570,000 | +13.8% | -51.4% | -5219.1% |
DERM Historical Revenue Data (2014–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $56.1M | -29.1% | $35.3M | 62.8% | $-13,677,000 | -24.4% |
| 2023 | $79.2M | +7.5% | $52.5M | 66.3% | $-2,073,000 | -2.6% |
| 2022 | $73.7M | +16.7% | $42.9M | 58.2% | $-27,517,000 | -37.4% |
| 2021 | $63.1M | +41.8% | $31.1M | 49.2% | $-34,881,000 | -55.2% |
| 2020 | $44.5M | +27.5% | $29.9M | 67.2% | $7.9M | 17.6% |
| 2019 | $34.9M | -17.5% | $24.4M | 69.8% | $5.3M | 15.1% |
| 2018 | $42.3M | +832.4% | $41.2M | 97.2% | $-213,982,000 | -505.4% |
| 2017 | $4.5M | -79.9% | $4.5M | 100.0% | $-300,326,000 | -6613.7% |
| 2016 | $22.6M | +209.4% | $22.6M | 100.0% | $-90,624,000 | -401.3% |
| 2015 | $7.3M | +0.0% | $7.3M | 100.0% | $-79,770,000 | -1092.7% |
See DERM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DERM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DERM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDERM — Frequently Asked Questions
Quick answers to the most common questions about buying DERM stock.
Is DERM's revenue growth accelerating or slowing?
DERM revenue growth slowed to +1.0%, below the 5-year CAGR of +10.0%. TTM revenue is $56M. The deceleration marks a shift from historical growth rates.
What is DERM's long-term revenue growth rate?
Journey Medical Corporation's 5-year revenue CAGR of +10.0% reflects the variable expansion pattern. Current YoY growth of +1.0% is near this long-term average.
How is DERM's revenue distributed by segment?
DERM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2024 are available for download. Segment mix reveals concentration and diversification trends.